US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology Market Research Reports & Industry Analysis

RSS Feeds

CNS/Neurology Industry Research & Market Reports

1  2    4    6  7  8  9  10  
Market Highlights: Europe Depression – 2014
5/1/2014 | published by: Fore Pharma
... research includes Europe (Germany, France, Italy, Spain, and UK) depression market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, ...  |  read more...
USD 2,800
Market Highlights: Spain Migraine – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, migraine drugs market share, migraine drugs sales estimates, migraine drugs sales forecast, and migraine late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Japan Migraine – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, migraine drugs market share, migraine drugs sales estimates, migraine drugs sales forecast, and migraine late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Europe Migraine – 2014
5/1/2014 | published by: Fore Pharma
... research includes Europe (Germany, France, Italy, Spain, and UK) migraine market size estimates for 2013, market share forecast for six years to 2019, migraine drugs market share, migraine drugs sales estimates, migraine drugs sales forecast, ...  |  read more...
USD 2,800
Market Highlights: Spain Bipolar Disorder – 2014
5/1/2014 | published by: Fore Pharma
... research includes Spain bipolar disorder market size estimates for 2013, market share forecast for six years to 2019, bipolar disorder drugs market share, bipolar disorder drugs sales estimates, bipolar disorder drugs sales forecast, and bipolar ...  |  read more...
USD 990
Market Highlights: US Bipolar Disorder – 2014
5/1/2014 | published by: Fore Pharma
... US. The research includes the US bipolar disorder market size estimates for 2013, market share forecast for six years to 2019, bipolar disorder drugs market share, bipolar disorder drugs sales estimates, bipolar disorder drugs sales ...  |  read more...
USD 990
Autism Global Clinical Trials Review, H1, 2014
5/30/2014 | published by: GlobalData
... relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
USD 2,500
PharmaPoint: Major Depressive Disorder - Current and Future Players
5/30/2014 | published by: GlobalData
... with in-depth analysis on the companies in the rapidly growing Major Depressive Disorder Market. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight ...  |  read more...
USD 2,995
PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such ...  |  read more...
USD 6,995
Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Alcohol Addiction - Pipeline Review, H1 2014
4/28/2014 | published by: Global Markets Direct
... therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
5/30/2014 | published by: GlobalData
... with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli ...  |  read more...
USD 3,495
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014
4/28/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
MediPoint: Neurovascular Interventions - Current and Future Players
4/30/2014 | published by: GlobalData
... and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices. The report identifies and analyzes ...  |  read more...
USD 3,500
Market Highlights: Spain Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in Spain. The research includes Spain attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: Germany Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in Germany. The research includes Germany attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: France Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in France. The research includes France attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
Market Highlights: Japan Attention Deficit Hyperactivity Disorder – 2014
5/1/2014 | published by: Fore Pharma
... hyperactivity disorder drug sales forecast in Japan. The research includes Japan attention deficit hyperactivity disorder market size estimates for 2013, market share forecast for six years to 2019, attention deficit hyperactivity disorder drugs market share, ...  |  read more...
USD 990
1  2    4    6  7  8  9  10